KR20180074797A - 통증 치료를 위한 오피오이드 작용제 및 오피오이드 길항제의 비-경피 전달된 n-옥시드 유도체를 포함하는 남용 방지 경피 전달 장치 및 조성물 - Google Patents

통증 치료를 위한 오피오이드 작용제 및 오피오이드 길항제의 비-경피 전달된 n-옥시드 유도체를 포함하는 남용 방지 경피 전달 장치 및 조성물 Download PDF

Info

Publication number
KR20180074797A
KR20180074797A KR1020187017271A KR20187017271A KR20180074797A KR 20180074797 A KR20180074797 A KR 20180074797A KR 1020187017271 A KR1020187017271 A KR 1020187017271A KR 20187017271 A KR20187017271 A KR 20187017271A KR 20180074797 A KR20180074797 A KR 20180074797A
Authority
KR
South Korea
Prior art keywords
oxide derivative
opioid
formula
oxide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187017271A
Other languages
English (en)
Korean (ko)
Inventor
스티브 화이트록
Original Assignee
유로-셀띠끄 소시에떼 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유로-셀띠끄 소시에떼 아노님 filed Critical 유로-셀띠끄 소시에떼 아노님
Publication of KR20180074797A publication Critical patent/KR20180074797A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020187017271A 2015-11-19 2016-11-18 통증 치료를 위한 오피오이드 작용제 및 오피오이드 길항제의 비-경피 전달된 n-옥시드 유도체를 포함하는 남용 방지 경피 전달 장치 및 조성물 Withdrawn KR20180074797A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1520390.4 2015-11-19
GBGB1520390.4A GB201520390D0 (en) 2015-11-19 2015-11-19 Composition
PCT/GB2016/053600 WO2017085502A1 (en) 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain

Publications (1)

Publication Number Publication Date
KR20180074797A true KR20180074797A (ko) 2018-07-03

Family

ID=55133015

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187017271A Withdrawn KR20180074797A (ko) 2015-11-19 2016-11-18 통증 치료를 위한 오피오이드 작용제 및 오피오이드 길항제의 비-경피 전달된 n-옥시드 유도체를 포함하는 남용 방지 경피 전달 장치 및 조성물

Country Status (14)

Country Link
US (1) US20180344726A1 (enExample)
EP (1) EP3377048B1 (enExample)
JP (1) JP2018534319A (enExample)
KR (1) KR20180074797A (enExample)
CN (1) CN108601747A (enExample)
AU (1) AU2016355113A1 (enExample)
BR (1) BR112018009886A2 (enExample)
CA (1) CA3005775A1 (enExample)
ES (1) ES2799516T3 (enExample)
GB (1) GB201520390D0 (enExample)
IL (1) IL259457A (enExample)
MX (1) MX2018006157A (enExample)
SG (1) SG11201803913RA (enExample)
WO (1) WO2017085502A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210078515A (ko) * 2018-10-18 2021-06-28 아비어, 인크. 만성 신장 질환-연관 소양증의 치료 방법 및 장치

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722928A (en) * 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
SI2283842T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
JP4949625B2 (ja) * 2002-06-10 2012-06-13 ユーロ−セルティーク エス．エイ． 経皮送達デバイスに含有された活性薬剤の誤用を防止する、経皮送達デバイスの廃棄システム
EP1718258B1 (en) * 2004-02-23 2009-03-25 Euro-Celtique S.A. Abuse resistance opioid transdermal delivery device
US20080234306A1 (en) * 2006-11-22 2008-09-25 Progenics Pharmaceuticals, Inc. N-Oxides of 4,5-Epoxy-Morphinanium Analogs
WO2009067275A1 (en) * 2007-11-21 2009-05-28 Progenics Pharmaceuticals, Inc N-oxides of 4,5-epoxy-morphinanium analogs
CA2718943A1 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
US8829020B2 (en) * 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
EP3064199B1 (en) * 2010-04-02 2023-12-20 Buzzz Pharmaceuticals Limited Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists

Also Published As

Publication number Publication date
US20180344726A1 (en) 2018-12-06
MX2018006157A (es) 2019-04-04
ES2799516T3 (es) 2020-12-18
EP3377048B1 (en) 2020-04-22
GB201520390D0 (en) 2016-01-06
CN108601747A (zh) 2018-09-28
EP3377048A1 (en) 2018-09-26
WO2017085502A1 (en) 2017-05-26
BR112018009886A2 (pt) 2018-11-13
IL259457A (en) 2018-07-31
CA3005775A1 (en) 2017-05-26
JP2018534319A (ja) 2018-11-22
SG11201803913RA (en) 2018-06-28
AU2016355113A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
CA2955247C (en) Abuse deterrent opiod/opiod-antagonist transdermal patch
US8481560B2 (en) Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
EP1530469B1 (en) Transdermal dosage form comprising an active agent and a salt and free-base form of an antagonist
US20080020028A1 (en) Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
AU2016244249B2 (en) Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20200276187A1 (en) Systems and methods for attenuating opioid-induced euphoria
EP3377048B1 (en) Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain
US9849124B2 (en) Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US10406154B2 (en) Transdermal dosage form
WO2020009685A1 (en) Transdermal dosage form
WO2020008366A1 (en) Transdermal dosage form
Schäfer Opioids in pain medicine

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180618

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid